Inventor · disambiguated record
Darko Skegro
Also filed as: SKEGRO DARKO
12 granted patents·22 pending applications·186 citations·filing 2010–2022
91Inventor score
Files withGLENMARK PHARMACEUTICALS SA13NOVARTIS AG12Ichnos Sciences SA4BLEIN STANISLAS3GRANDA BRIAN1
Top patents by PatentIndex Score
34 records- 0196US9493563B2Production of T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Nov 15, 2016·47 cites·3 claims
- 0294US11891454B2Production of T cell retargeting hetero-dimeric immunoglobulinsIchnos Sciences SA·Filed 2020·Granted Feb 6, 2024·3 cites·15 claims
- 0394US9683053B2Hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Jun 20, 2017·38 cites·21 claims
- 0492US9683052B2Hetero-dimeric immunoglobulinsBLEIN STANISLAS·Filed 2012·Granted Jun 20, 2017·26 cites·10 claims
- 0592US9290576B2Antibodies that bind to TL1A and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Mar 22, 2016·22 cites·51 claims
- 0689US11773166B2CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their productionIchnos Sciences SA·Filed 2018·Granted Oct 3, 2023·5 cites·12 claims
- 0789US8679492B2Humanized antibodies that bind to CD19 and their usesBLEIN STANISLAS·Filed 2010·Granted Mar 25, 2014·35 cites·15 claims
- 0888US11851502B2Production of T cell retargeting hetero-dimeric immunoglobulinsIchnos Sciences SA·Filed 2018·Granted Dec 26, 2023·3 cites·13 claims
- 0982US8975376B2Anti-alpha2 integrin antibodies and their usesBLEIN STANISLAS·Filed 2011·Granted Mar 10, 2015·7 cites·14 claims
- 1072US12006367B2CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their productionIchnos Sciences SA·Filed 2022·Granted Jun 11, 2024·0 cites·9 claims
- 1165US2020024367A1Hetero-Dimeric ImmunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 1261US2017145115A1Production of T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 1359US2018094077A1Hetero-Dimeric ImmunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2017·Application pending·0 cites
- 1457US2020079863A1Antibodies that bind to tl1a and their usesGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 1556US2024002509A1ANTIBODY Fc VARIANTSNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1656US2023265160A1Therapeutic fusion proteinsNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1756US2025000973A1Methods of making chimeric antigen receptor-expressing cellsNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1856US2023220048A1Therapeutic fusion proteinsNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1956US2023308835A1Therapeutic fusion proteinsNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2055US11685776B2Engineered heterodimeric proteinsNOVARTIS AG·Filed 2018·Granted Jun 27, 2023·0 cites·16 claims
- 2154US2015183885A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 2253US2025215081A1Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignanciesNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2353US2025011428A1Engineered fc variantsNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2451US2018086840A1Antibodies that bind to tl1a and their usesGLENMARK PHARMACEUTICALS SA·Filed 2017·Application pending·0 cites
- 2550US2023242647A1Engineered immunoglobulinsNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2650US2024025993A1Cd19 binding molecules and uses thereofNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2750US2023167193A1Immunoglobulin variantsNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2849US2023302155A1Compositions and methods for in vivo generation of car expressing cellsNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2949US2013344064A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2013·Application pending·0 cites
- 3049US2016319027A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 3147US2014286934A1Humanized antibodies that bind to cd19 and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 3246US11267891B2Fc variant antibodies and their usesSANOFI SA·Filed 2015·Granted Mar 8, 2022·0 cites·10 claims
- 3344US2017218087A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 3439US2020362054A1Trispecific binding molecules against tumor-associated antigents and use thereofGRANDA BRIAN·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Darko Skegro files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →